Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II cisplatin plus everolimus in extrapulmonary neuroendocrine carcinoma
NL-OMON47011Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and everolimus in extrapulmonary neuroendocrine carcinoma (EPNEC) and Merkel cell carcinoma (MCC), sponsored by Netherlands Cancer Institute. Primary endpoint: Disease control rate. Started Mar 2016; status: completed.
02
Drugs
cisplatineverolimus
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NL-OMON47011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47011.